Sotalol

Introduction Overview

Generic Name

sotalol

Brand Name

Betapace, Betapace AF, Sorine, Sotalol Hydrochloride AF, Sotylize

Dosage Form

intravenous solution (15 mg/mL), oral solution (5 mg/mL), oral tablet (80 mg; 120 mg; 160 mg; 240 mg; AF 80 mg; AF 120 mg; AF 160 mg)

Drug Class

Group III antiarrhythmics, Non-cardioselective beta blockers

Pharmacokinetics

Absorption:
Sotalol is administered both orally and intravenously, ensuring flexible clinical use. After oral administration, sotalol is rapidly and almost completely absorbed from the gastrointestinal tract, with bioavailability approaching 90-100%. The drug is not subject to significant first-pass metabolism, facilitating consistent systemic availability. Its absorption is not notably affected by food, although antacids can interfere with absorption if taken within 2 hours before or after dosing, likely due to pH changes and chelation effects within the gut lumen.

Distribution:
Sotalol exhibits a relatively low protein binding profile, approximately 0-30%, indicating a substantial fraction remains free in plasma to exert pharmacologic effects. It distributes widely through body tissues, including cardiac tissue, allowing effective modulation of myocardial electrophysiology. The apparent volume of distribution is moderate, at approximately 2-3 L/kg, reflecting distribution beyond the vascular compartment but limited penetration into the central nervous system due to hydrophilic nature.

Metabolism:
Unique among many beta blockers, sotalol undergoes minimal hepatic metabolism, with the majority of the administered dose circulating as unchanged drug. This feature contributes to predictable pharmacokinetics and fewer drug-drug metabolic interactions. Due to minimal metabolism, sotalol's elimination is predominantly dependent on renal clearance rather than hepatic enzymatic activity.

Elimination:
Renal elimination is the primary pathway for sotalol excretion, with approximately 80-90% of unchanged drug recovered in urine. It undergoes glomerular filtration and active tubular secretion. The elimination half-life ranges typically from 12 to 20 hours in patients with normal renal function; however, half-life can be significantly prolonged in renal impairment, necessitating dosage adjustments to minimize the risk of drug accumulation and associated proarrhythmic adverse effects. Continuous monitoring of renal function and serum potassium is critical during therapy. Steady-state concentrations are generally reached within 2 to 3 days of consistent dosing.

Dosage Forms

Available Dosage Forms:
Sotalol is available in multiple formulations designed to meet various clinical needs. These include:
- Oral tablets: 80 mg, 120 mg, 160 mg, and 240 mg, with specific formulations designated as Sotalol AF 80 mg, 120 mg, and 160 mg tailored for atrial fibrillation/flutter treatment.
- Oral solution: 5 mg/mL, providing dosing flexibility especially in pediatric patients or those unable to swallow tablets.
- Intravenous solution: 15 mg/mL, used primarily for inpatient management when oral administration is not feasible or rapid onset of steady-state drug concentration is desired.

Dosages for Adults and Adolescents:
The initial recommended oral dose in adults is typically 80 mg twice daily, with clinical titration based on therapeutic response and tolerance. Maximum dosing rarely exceeds 160 mg twice daily due to the dose-dependent risk of QT prolongation. For atrial fibrillation/flutter maintenance therapy, specific formulations labeled AF are utilized with appropriate dose adjustments.

Specific Patient Populations:
Dosing adjustments are necessitated in patients with impaired renal function due to the renal elimination of sotalol. Creatinine clearance-guided dosing modifications are critical to avoid accumulation and toxicity. Pediatric dosing is generally weight- and surface area-based due to the paucity of extensive clinical trial data and to accommodate differing pharmacokinetics in children. Regular monitoring of heart rhythm and renal function is essential during therapy initiation and ongoing treatment.

Mechanism Of Action

Sotalol exerts its antiarrhythmic effects through a unique combination of pharmacodynamic properties by serving both as a non-selective beta-adrenergic receptor blocker and a potassium channel blocker. Primarily, it antagonizes beta-1 and beta-2 adrenergic receptors, reducing sympathetic stimulation of the heart. This blockade leads to decreased heart rate, myocardial contractility, and conduction velocity, which are critical for controlling arrhythmias.

In addition to its beta-blocking action, sotalol prolongs the cardiac action potential by blocking the delayed rectifier potassium channels (IKr), a characteristic of Class III antiarrhythmic agents. This effect prolongs the repolarization phase and refractory period of atrial and ventricular myocardium, thereby suppressing abnormal automaticity and reentrant tachyarrhythmias. Importantly, this potassium channel blockade contributes to prolongation of the QT interval, a factor significant both in therapeutic efficacy and risk of proarrhythmia.

At the cellular level, sotalol modulates ion fluxes by inhibiting outward potassium currents, stabilizing myocardial cells against premature depolarizations while its beta-blocking reduces intracellular cyclic AMP-mediated signaling. This dual mechanism affords sotalol efficacious control of various tachyarrhythmias including atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.

Clinically, sotalol's combined beta-adrenergic and Class III antiarrhythmic properties distinguish it from selective beta blockers and pure potassium channel blockers, offering broad-spectrum antiarrhythmic efficacy. However, the risk of QT prolongation and torsades de pointes necessitates cautious initiation and monitoring. Comparative studies show that while other Class III agents like amiodarone may have different side effect profiles, sotalol’s predictable pharmacokinetics and lack of extensive metabolism are advantageous in specific populations.

Pharmacological Actions

Non-selective beta-adrenergic receptor antagonist blocking both beta-1 and beta-2 receptors.
Class III antiarrhythmic action via blockade of cardiac delayed rectifier potassium channels (IKr), prolonging repolarization.
Negative chronotropic effect leading to decreased heart rate.
Negative inotropic effect reducing myocardial contractility.
Negative dromotropic effect delaying atrioventricular nodal conduction.
Reduction in sympathetic nervous system stimulation of the heart.
Prolongation of myocardial action potential duration and refractory period in atrial and ventricular tissue.
Suppression of reentrant tachyarrhythmias by increasing effective refractory period.
Stabilization of myocardial electrical activity preventing premature depolarizations.
Minimal hepatic metabolism promoting predictable pharmacokinetics.
Reduction of myocardial oxygen demand due to decreased heart rate and contractility.
Limited penetration of blood-brain barrier due to hydrophilicity.
Decrease in sinus node automaticity contributing to antiarrhythmic effects.

Therapeutic Or Clinical Uses

Maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation or atrial flutter (primarily using Sotalol AF formulations).
Treatment and prophylaxis of life-threatening ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation.
Management of supraventricular arrhythmias, particularly atrial fibrillation and atrial flutter.
Reduction of ventricular rate in tachyarrhythmias through beta-blockade.
Used in patients requiring both beta-blockade and Class III antiarrhythmic effects.
Alternative to other antiarrhythmics for patients intolerant to amiodarone or flecainide.
Post-myocardial infarction arrhythmia control in selected patients with preserved left ventricular function.
Used in electrophysiology laboratories during initiation and adjustment of antiarrhythmic therapy to prevent arrhythmia recurrence.
Off-label uses include management of certain refractory tachyarrhythmias in pediatric populations under specialist supervision.
May be utilized in settings requiring intravenous antiarrhythmic administration when oral intake is impractical or urgent therapy is needed.

Side Or Adverse Effects

Bradycardia including symptomatic slow heart rate.
QT interval prolongation with risk of torsades de pointes and other ventricular arrhythmias.
Fatigue and asthenia related to beta-blockade.
Dizziness and light-headedness potentially due to hypotension or bradycardia.
Shortness of breath, bronchospasm especially in patients with reactive airway diseases.
Nausea and vomiting.
Worsening of heart failure symptoms in susceptible individuals.
Hypotension, sometimes causing syncope or fainting.
Peripheral edema secondary to fluid retention.
Cold extremities due to decreased peripheral circulation.
Sleep disturbances, including insomnia or vivid dreams.
Exacerbation of hypoglycemia unawareness in diabetic patients.
Allergic reactions including rash, urticaria, and rarely anaphylaxis.
Electrolyte disturbances such as hyperkalemia when used with other agents.
Potential worsening of asthma or chronic obstructive pulmonary disease.

Precautions

Monitor renal function closely due to predominant renal elimination; adjust dose accordingly in renal impairment.
Initiate sotalol therapy in a hospital setting with continuous ECG monitoring for at least 3 days to monitor QT interval and arrhythmias.
Correct electrolyte abnormalities, especially hypokalemia and hypomagnesemia, before and during treatment to reduce proarrhythmic risk.
Avoid abrupt discontinuation to prevent exacerbation of arrhythmias and sympathetic rebound effects.
Caution in patients with heart failure; monitor for clinical signs of worsening cardiac function.
Avoid use in patients with asthma or reactive airway disease due to risk of bronchospasm.
Assess baseline QTc interval; contraindicated if QTc is >450 ms, with dose reduction or discontinuation if QTc exceeds 500 ms during therapy.
Caution in patients with borderline bradycardia, sick sinus syndrome, or conduction abnormalities unless pacemaker is present.
Avoid concurrent use with other drugs that prolong QT interval or reduce potassium/magnesium.
Avoid in patients with severe kidney disease, particularly those on dialysis for atrial fibrillation/flutter indication.
Pregnancy: use only if benefits outweigh risks; cross placenta and may affect fetal heart rhythm and development.
Do not breastfeed during treatment due to potential drug transmission and fetal effects.
Caution in diabetic patients as sotalol may mask symptoms of hypoglycemia.
Patients should be advised to report signs of dyspnea, dizziness, palpitations, or syncope promptly.
Avoid antacids within 2 hours of dosing to prevent impaired absorption.

Warnings

Contraindicated in patients with asthma or bronchospastic conditions due to risk of life-threatening bronchospasm.
Prolongs QT interval, which can precipitate torsades de pointes, a potentially fatal ventricular arrhythmia.
Avoid initiation in patients with baseline QTc interval >450 ms; monitor ECG regularly during therapy.
Life-threatening ventricular tachycardia, including torsades de pointes, has been associated with sotalol especially during initiation.
Requires inpatient monitoring with continuous cardiac resuscitation readiness for initiation or reinitiation.
Should not be used in patients with sick sinus syndrome or AV block unless a permanent pacemaker is in place.
Contraindicated in severe heart failure due to potential exacerbation and hemodynamic compromise.
Do not substitute different brand formulations of sotalol without physician guidance due to variations in labeling and pharmacodynamics.
Use with extreme caution in patients with electrolyte imbalances such as hypokalemia or hypomagnesemia.
Discontinue or reduce dose if QTc interval prolongs to 500 ms or greater or if serious arrhythmias develop.
Pregnancy and breastfeeding warnings due to potential adverse fetal and neonatal effects.
Avoid sudden discontinuation to prevent rebound tachycardia or hypertension.
Concurrent use with other beta blockers or antiarrhythmics should be closely evaluated to prevent additive adverse effects.
Use caution in patients with bradyarrhythmias to reduce risk of symptomatic bradycardia or conduction blocks.
Caution with use in elderly due to increased risk of adverse cardiac reactions.

Contraindication

Known hypersensitivity to sotalol or any inactive tablet ingredients.
Asthma or other bronchospastic lung diseases.
Uncontrolled severe heart failure or decompensated heart failure.
Sick sinus syndrome or second/third degree atrioventricular (AV) block without pacemaker.
Long QT syndrome (congenital or acquired) in patient or family history.
Baseline corrected QT interval (QTc) greater than 450 milliseconds prior to intravenous initiation.
Symptomatic bradycardia or slow heartbeats that have caused syncope.
Severe renal impairment, specifically when used for atrial fibrillation/flutter indications.
Use in newborns or pediatric patients without careful medical supervision and dose adjustment.
Concurrent administration with potent inducers or inhibitors that may alter sotalol concentration without monitoring.
Concomitant use with other drugs known to markedly prolong the QT interval is contraindicated.
Hypersensitivity to beta blockers in general.
Severe hypotension or shock states.
Patients with untreated pheochromocytoma without alpha blockade.
Concurrent use is contraindicated with heart rate-lowering agents causing severe bradycardia unless monitored.

Drug Interactions

Antacids can reduce the absorption of orally administered sotalol if taken within 2 hours before or after dosing.
Concurrent use with other QT-prolonging drugs (e.g., class I and III antiarrhythmics, certain antipsychotics) increases risk of torsades de pointes.
Other beta blockers or calcium channel blockers (e.g., verapamil, diltiazem) can have additive negative chronotropic and inotropic effects, increasing risk of bradycardia and heart block.
Drugs that alter renal function or potassium balance (e.g., diuretics, ACE inhibitors, ARBs) can potentiate sotalol toxicity or proarrhythmia.
Insulin and other oral antidiabetic drugs may have masked hypoglycemia symptoms when combined with sotalol.
Clonidine coadministration may potentiate bradycardia and hypotension.
Albuterol, terbutaline, and other beta-agonists may antagonize the beta-blocking effects of sotalol, reducing efficacy.
Digoxin’s cardiac effects may be potentiated by sotalol increasing risk of bradyarrhythmias.
Drugs reducing serum potassium or magnesium (e.g., laxatives, corticosteroids) increase proarrhythmic risk when used with sotalol.
Concurrent use with other antiarrhythmics requires caution due to additive electrophysiological effects and toxicity.
Non-steroidal anti-inflammatory drugs (NSAIDs) may reduce antihypertensive effect of sotalol.
Use with potent cytochrome P450 inhibitors or inducers does not impact sotalol metabolism significantly, but clinical vigilance is advised.
Avoid simultaneous use with sympathomimetics due to opposing pharmacodynamic effects.
Caution with anesthetics and neuromuscular blockers as sotalol may amplify cardiac depression during procedures.
Herbal supplements such as St. John's Wort may have unpredictable interactions impacting cardiac rhythm.

Preparations Of The Drug

Sotalol hydrochloride oral tablets in 80 mg, 120 mg, 160 mg and 240 mg strengths.
Sotalol hydrochloride oral tablets labeled as Sotalol AF available in 80 mg, 120 mg, and 160 mg specifically for atrial fibrillation/flutter maintenance.
Oral solution containing 5 mg/mL concentration for flexible dosing in pediatric or dysphagic patients.
Intravenous solution with concentration of 15 mg/mL for hospital use, enabling controlled titration and rapid attainment of therapeutic plasma levels.
Tablets composed of active sotalol hydrochloride and excipients such as colloidal silicon dioxide, hydroxypropyl cellulose, lactose anhydrous and monohydrate, magnesium stearate, pregelatinized starch, sodium starch glycolate, and coloring agents (e.g., FD&C blue No. 1 aluminum lake).
Packaging compliant with regulatory standards to ensure stability, including moisture and heat protection.
Formulations supplied by multiple manufacturers, necessitating attention to brand-specific prescribing information.
Patient package inserts provided especially with Sotalol AF formulations to guide usage in atrial fibrillation/flutter.
Supply formats suitable for both outpatient and inpatient settings with appropriate labeling and dosing instructions.
Parenteral formulations intended strictly for intravenous use under healthcare supervision with cardiac monitoring.